New Clinical Developments and Advanced Clinical Studies Offer Superior Treatment Options - Research Report on Alnylam,

    New Clinical Developments and Advanced Clinical Studies Offer Superior
    Treatment Options - Research Report on Alnylam, Immunomedics, Tesaro,
                             InterMune and Synta

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, June 27, 2013

NEW YORK, June 27, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Immunomedics Inc. (NASDAQ: IMMU),
Tesaro, Inc. (NASDAQ: TSRO), InterMune Inc. (NASDAQ: ITMN) and Synta
Pharmaceuticals Corp. (NASDAQ: SNTA). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Alnylam Pharmaceuticals, Inc. Research Report

On June 20, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that it
presented pre-clinical data with ALN-CC5, an RNAi therapeutic targeting
complement component C5, at the 6^th International Conference on Complement
Therapeutics, which was held from June 18 to June 23, 2013 in Greece. The
presentation, "Development of an RNAi Therapeutic Silencing the C5 Component
of Complement," showed the potent, dose-dependent, and durable RNAi-mediated
knockdown of serum C5 and inhibition of complement-mediated hemolytic activity
of approximately 90% with a subcutaneously administered RNAi therapeutic. "C5
is a genetically and clinically validated target that exemplifies the
potential of Alnylam's '5x15' product strategy for innovative new medicines.
First, C5 is predominantly expressed in liver, where we have established
clinical activity and tolerability for RNAi therapeutics. In addition, our
clinical development plan for an RNAi therapeutic targeting C5 will be
facilitated by serum biomarkers in Phase I trials and a relatively streamlined
and focused path for advanced development," said Rachel Meyers, Ph.D., Vice
President, Research and RNAi Lead Development at Alnylam. The Full Research
Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: []


Immunomedics Inc. Research Report

On June 13, 2013, Immunomedics Inc. (Immunomedics) announced that UCB reported
new data from an open-label extension of the EMBLEM phase 2b study evaluating
the long-term effects of epratuzumab treatment in adult patients with
moderate-to-severe systemic lupus erythematosus (SLE). "In EMBLEM, a
dose-ranging, phase 2b study, reduction in disease activity was observed in
patients treated with epratuzumab," said Professor Daniel J Wallace MD,
Clinical Professor of Medicine, Cedars-Sinai Medical Center, California, US.
He added, "This double-blind study had a relatively short 12-week,
placebo-controlled, treatment period and it was important to accumulate
long-term data on epratuzumab in the treatment of SLE. The phase 2b extension
study adds new two year open-label data on epratuzumab to that already
available from the 12-week, randomized, controlled study." The Full Research
Report on Immunomedics Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:


Tesaro, Inc. Research Report

On June 4, 2013, TESARO Inc. (Tesaro) announced the final results from a Phase
1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP).
Tesaro reported that at a dose of 300 milligrams once daily, 75% with platinum
sensitive high grade serous ovarian cancer achieved a RECIST response, and
across all dose levels (30 milligrams to 400 milligrams daily), a RECIST
response rate of 46% was observed within this population. Also, a RECIST
response rate of 50% was achieved in patients with platinum sensitive ovarian
cancer and germline BRCA mutations. Dr. Mary Lynne Hedley, President of TESARO
commented, "The results of this study provide further support for the design
of our planned Phase 3 trials in ovarian and breast cancer and, in particular,
the potential utility of platinum sensitivity and BRCA status as predictors of
response to niraparib." The Full Research Report on Tesaro, Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


InterMune Inc. Research Report

On June 14, 2013, InterMune, Inc. (InterMune) announced that the Board of the
Italian Drug Agency (AIFA) has approved the pricing and reimbursement
conditions for Esbriet (pirfenidone), and that the agreement has been
published in the Official Gazette, the official journal of the government of
Italy. Esbriet is InterMune's product for the treatment of adult patients with
mild to moderate idiopathic pulmonary fibrosis (IPF). Giacomo Di Nepi,
Executive Vice President and Managing Director, Europe for InterMune, said,
"We are very pleased to see the publication of our pricing and reimbursement
agreement, which allows us to make Esbriet available very soon to Italian
patients with mild to moderate IPF. Our entire organization is prepared to
launch Esbriet in Italy and our Italian team is excited and fully committed to
making Esbriet available to all appropriate IPF patients as rapidly as
possible." The Full Research Report on InterMune Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:


Synta Pharmaceuticals Corp. Research Report

On June 3, 2013, Synta Pharmaceuticals Corp. (Synta) announced the results
from an interim survival analysis of the GALAXY-1 TRIAL, a study designed to
evaluate the efficacy and safety of the Company's lead drug candidate, the
Hsp90 inhibitor ganetespib, as second-line treatment for patients with
advanced non-small cell lung adenocarcinoma. The results show that the
combination of ganetespib plus docetaxel improves overall survival and
progression-free-survival compared to docetaxel alone. "Outside of certain
genetically-defined patient populations, there have been no new options for
the treatment of patients with non-small cell adenocarcinoma following
first-line therapy in nearly a decade," said Dr. Dean A. Fennell, University
Hospital, Leicester, UK, co-Principal Investigator of GALAXY-1. He further
added, "The magnitude and consistency of the activity reported today are very
encouraging and bode well for the outcome of the GALAXY-2 Phase 3 study." The
Full Research Report on Synta Pharmaceuticals Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: []



1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
5.For any urgent concerns or inquiries, please contact us at
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: Phone #: +1-310-496-8071 (North America)
Press spacebar to pause and continue. Press esc to stop.